STOCK TITAN

Stevanato Group Spa - STVN STOCK NEWS

Welcome to our dedicated news page for Stevanato Group Spa (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group Spa.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stevanato Group Spa's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stevanato Group Spa's position in the market.

Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) appoints Ugo Gay as Chief Operations Officer to enhance operational efficiency and growth. Ugo Gay brings 30 years of experience to drive standardization and strategic development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
management
-
Rhea-AI Summary
Stevanato Group (STVN) closes upsized public offering, selling 14.6 million ordinary shares at $26.00 per share, generating approximately $379.7 million in gross proceeds. The Company intends to use the net proceeds for general corporate purposes and ongoing investment activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
-
Rhea-AI Summary
Stevanato Group (STVN) announces the pricing of its upsized underwritten public offering of 12,700,000 ordinary shares at $26.00 per share, with expected gross proceeds of approximately $330 million. The Company intends to use the net proceeds for general corporate purposes and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.54%
Tags
Rhea-AI Summary
Stevanato Group (STVN) announces a $300 million underwritten public offering of ordinary shares. The Company and a major shareholder are each offering $150 million. The underwriters have an option to purchase additional shares. The net proceeds will be used for general corporate purposes and investment activities. Morgan Stanley and William Blair are the joint book-running managers for the Offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
-
Rhea-AI Summary
Stevanato Group S.p.A. (STVN) will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 19-20, 2024. The Company will present on March 19, 2024, at 1:30 p.m. (ET), with a live webcast on their website. A replay will be available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
conferences
-
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) announces its financial results for Q4 and FY 2023, reporting a 10% revenue increase to €320.6 million in Q4 and €1,085.4 million for FY 2023. Adjusted EBITDA margins were 27% for Q4 and 26.9% for FY 2023. The company sets guidance for FY 2024 with revenue expected between €1,180 million to €1,210 million, adjusted EBITDA between €314.1 million to €329.5 million, and adjusted diluted EPS between €0.62 and €0.66.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) will release its financial results for the fourth quarter and year end of 2023 on March 7, 2024. A conference call and webcast will be held to discuss the results, with pre-registration available for immediate access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.23%
Tags
conferences earnings
-
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) has introduced two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers. The EZ-fill® Kit provides fast access to a customizable and versatile solution for efficiently filling small batches with high-quality injectable formulations. The surge in biopharmaceuticals treating various diseases signals significant growth potential for pharmaceutical companies. The kit brings enhanced levels of quality and safety to patients and is expected to be available commercially beginning in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
-
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) will participate in the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco. The company will present on January 10th at 8:15 a.m.(PT) and provide a live webcast on their website. A replay of the webcast will be available for approximately 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
Rhea-AI Summary
Stevanato Group (NYSE: STVN) Wins 2023 Pharma Innovation Award for Mavis™ Combi Visual Inspection Machine, Recognized for Excellence and Leadership in Implementing Equipment and Technology to Respond to Pharma Companies’ Needs. The Mavis™ Combi is a cutting-edge solution designed to enhance visual inspection of primary packaging and drugs, providing advanced performance, flexibility, and speed. It can handle a diverse array of glass primary containers, accurately identifying particles, cosmetic defects, and closure integrity issues, ensuring the highest standards of product quality and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
none
Stevanato Group Spa

NYSE:STVN

STVN Rankings

STVN Stock Data

8.02B
41.66M
2.13%
77.59%
0.87%
Glass Container Manufacturing
Manufacturing
Link
Italy
Piombino Dese

About STVN

founded in 1949, stevanato group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. it is comprised of two operational divisions: - pharmaceutical systems (ompi and balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. - engineering systems (spami, optrel, innoscan and svm brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. these two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that stevanato group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. the group also benefits from the sglab activ